[ad_1]
“This is the first vaccine to be administered in a single dose,” said Emer Cooke, director of the Amsterdam-based European Medicines Agency (EMA).
The EEA has announced that it will recommend that the vaccine be approved for use in all persons over 18 years of age when a ‘comprehensive evaluation’ of the data provided by Johnson & Johnson shows that the vaccine meets the criteria for efficacy, safety and quality.
“With this latest positive conclusion, all authorities in the European Union will have one more option to face the pandemic and protect the life and health of its citizens,” Cooke said.
To date, EVA has approved vaccines from Pfizer, BioNTech, Moderna, and AstraZeneca, but they require two doses administered a few weeks apart.
According to the report, the effectiveness of the Johnson & Johnson vaccine is 67 percent.
The Johnson & Johnson vaccine was approved by the US Food and Drug Administration in late February. Health experts hope that the single-dose vaccine will speed up the COVID-19 vaccination process around the world, especially given the new strains of the virus that have been spreading in recent months.
The European Union has faced challenges in rapidly distributing the vaccine and vaccinating the most vulnerable members of society. The Community ranks Israel, the United Kingdom, Chile, and the United States in terms of vaccination coverage.
About a million new infections were detected in Europe last week, 9% more than the previous week. In addition, the jump in cases interrupted the record six-week decline in new infections. The European Office of the World Health Organization attributes this in part to new strains, including the “British” variant of the virus, which is believed to be 50% spread. faster.
A study of the Johnson & Johnson vaccine on three continents shows that it is 85 percent effective in preventing serious forms of illness, hospitalization, and death. This protection has remained strong even in countries like South Africa, where variants have been identified that appear to be less sensitive to other licensed vaccines, including AstraZeneca.
Approved by the European Commission
The European Commission approved the distribution of a single-dose COVID-19 vaccine by US pharmaceutical giant Johnson & Johnson on Thursday, following a decision by the European Medicines Agency (EMA).
“Safer and more effective vaccines are coming to the market,” EC President Ursula von der Leyen wrote on Twitter.
“We have just approved the use of the Johnson & Johnson vaccine in the European Union … Now, with the number of doses of vaccine that we have requested, we can [šiais metais] vaccinated in the EU up to 200 million people ”, he added.
[ad_2]
